138 companies in the first three quarters of net profit increase of 18% pharmaceutical industry sector recovery is evident

Wind data show that as of October 24, 149 of the 213 pharmaceutical listed companies had disclosed their third-quarter earnings forecasts. Of these, 94 companies had increased net profit, 48 had fallen and seven remained uncertain. Listed companies in the pharmaceutical industry have achieved a good harvest, or steady growth, which means that the pharmaceutical industry gradually through the winter. According to the data over the past two years, the average growth rate of net profit in the pharmaceutical industry sector is slower than the industry average, and the third quarter report is showing signs of recovery. Most listed companies in the first three quarters of the results often give the full-year operating results "set the tone", the market attention is quite high.Pharma Industry Recovery
among the 149 companies mentioned above, 11 companies, including Shangrong Medical, Hengkang Medical, Fish Leap Medical and Yan Yan Pharmaceuticals, were excluded, and 138 companies belonged to the pharmaceutical industry subdivision. The 138 companies reported an average year-on-year increase in operating income of about 7.7 per cent in the January-September period, compared with 5 per cent in the semi-annual report, while net profit increased by an average of about 18 per cent year-on-year and about 16 per cent in the half-yearly report. According to the Ministry of Industry and Information Technology, the first half of the country's pharmaceutical manufacturing revenue increased by about 10% year-on-year, net profit increased by an average of about 14% year-on-year. The growth rate of net profit of listed companies is better than the industry average.
26 companies are expected to grow net profit by more than 100% in the third quarter, including Guangyuyuan, Tonghua Jinma, Guangji Pharmaceuticals, Zixin Pharmaceuticals, Guo Nong Technology, Taiji Group, Four Rings Biology, Tiantan Bio, Zixin Pharmaceuticals, etc. The general reason for the growth in performance is the expansion of sales and the profit growth point of new products listed on the market. The increase in individual pharmaceutical companies was due to a smaller profit base in the same period last year, including agricultural technology, while the growth momentum of Peking University Pharmaceuticals was mainly due to the disposal of non-performing assets.
10 companies with net profit growth of between 50% and 100%, respectively, Zhendong Pharmaceuticals, Fuxiang Shares, Asia Pacific Pharmaceuticals, Shandahuat, Jindawei and so on. Among them, Jindawei performance growth is due to the increase in vitamin A prices, Boya Bio's performance growth is due to the rise in blood products prices. The rest of the company basically brought a rise in net profit as a result of the expansion in sales.
46 other companies in the U.S. have increased their net profits by 0%-30%, and seven companies are uncertain. Of the 48 companies with year-on-year declines, five have seen declines of 100-700%, namely Zhifei Bio, Watson Bio (, Shuangcheng Pharmaceuticals, Chengzhi Shares) and Shuangcheng Pharmaceuticals. Zhifei bio and Watson bio because of the "toxic vaccine" event, its vaccine product circulation channels affected, in the short term to the company's vaccine product sales caused a greater impact.market pattern has changed dramaticly
with the advance of new medical reform, the pharmaceutical market pattern has changed dramaticly, the industry is facing unprecedented challenges. The economic growth rate is slowing down, the medical insurance control fee is becoming stricter, the proportion of hospital drugs is getting smaller and smaller, the drug flight inspection is strengthened, the price of drug tenders and the restrictions on auxiliary drugs, antibiotics, large infusions and so on are becoming more and more severe. In particular, the full-scale development of medical insurance charges, breaking the traditional growth model of the pharmaceutical industry relying on medical insurance expansion, the industry entered a difficult transition period, plate differentiation is inevitable.
, president of the China Pharmaceutical Enterprise Management Association, told China Securities News that in the first half of 2015, revenue growth in the pharmaceutical manufacturing industry hit a 15-year low of 8.76 percent. Industry revenue growth fell below 10%, only before 2000, when the urban workers' health care system was missing. At a time when aging demand is releasing, it is worth noting that growth has fallen below double digits. In the first half of this year, revenues in the pharmaceutical manufacturing sector grew by 10%, returning to double-digit levels and rebounding from a year earlier.
Jianning, director of the Southern Institute of Pharmaceutical Economics of the State Administration of Food and Drug Administration, told China Securities News that revenue growth in the pharmaceutical manufacturing industry is expected to be about 11.3% in 2016, with an output value of 3.2 trillion yuan.
, a fund manager at the Agricultural Bank of China Healthcare Fund, believes that the pharmaceutical sector is now more cost-effective. At present, the market is too concerned about the impact of policy, such as fear that the "three-ming model" promotion will bring greater lethality, in fact, the "three-ming model" is difficult to promote. Meanwhile, the industry's lowest point is over. In March and April, industry revenue reached more than 10% for two consecutive months, and profits increased by more than 15%. In addition, the overall market allocation of the pharmaceutical sector is low. Until 2016, the allocation of funds in the pharmaceutical industry was rarely less than 15%, and it is estimated to be around 8% to 9%. (China Securities News)